Clinical characteristics of study subjects
| Study (n) . | Ascertainment criteria . | Autoantibody positivity* . | Range of age at onset (years) . | Age at onset (years) . | Duration of diabetes (years) . | BMI (kg/m2) . | Male sex (%) . | Insulin requiring by 3 years postdiagnosis (%) . |
|---|---|---|---|---|---|---|---|---|
| UKPDS (232) | Newly diagnosed type 2 diabetes: not insulin requiring within 3 months of diagnosis, ketonuria <3 mmol/l | GADA and/or IA-2A† | 25–65 | 46.7 ± 10.6 | Studied at diagnosis | 25.2 ± 4.9† | 53 | 51 |
| W2 Repository (131) | Clinical diagnosis of type 2 diabetes: not insulin requiring within 12 months of diagnosis | GADA‡ | 26–68 | 47.4 ± 10.0 | 8.9 ± 6.7‡ | 28.6 ± 5.3‡ | 57 | 41 |
| Exeter YT2D (37) | Clinical diagnosis of type 2 diabetes: not insulin requiring within 3 months of diagnosis | GADA and/or IA-2A‡ | 29–45 | 38.4 ± 5.4 | 11.9 ± 7.7‡ | 27.5 ± 5.8‡ | 43 | 57 |
| Control subjects (332) | Spouses/friends of probands collected in the DIF study, normoglycemic | Negative for GADA and IA-2A‡ | 20–91‡ | 55.5 ± 19.8‡ | N/A | 25.4 ± 4.0‡ | 45 | N/A |
| Study (n) . | Ascertainment criteria . | Autoantibody positivity* . | Range of age at onset (years) . | Age at onset (years) . | Duration of diabetes (years) . | BMI (kg/m2) . | Male sex (%) . | Insulin requiring by 3 years postdiagnosis (%) . |
|---|---|---|---|---|---|---|---|---|
| UKPDS (232) | Newly diagnosed type 2 diabetes: not insulin requiring within 3 months of diagnosis, ketonuria <3 mmol/l | GADA and/or IA-2A† | 25–65 | 46.7 ± 10.6 | Studied at diagnosis | 25.2 ± 4.9† | 53 | 51 |
| W2 Repository (131) | Clinical diagnosis of type 2 diabetes: not insulin requiring within 12 months of diagnosis | GADA‡ | 26–68 | 47.4 ± 10.0 | 8.9 ± 6.7‡ | 28.6 ± 5.3‡ | 57 | 41 |
| Exeter YT2D (37) | Clinical diagnosis of type 2 diabetes: not insulin requiring within 3 months of diagnosis | GADA and/or IA-2A‡ | 29–45 | 38.4 ± 5.4 | 11.9 ± 7.7‡ | 27.5 ± 5.8‡ | 43 | 57 |
| Control subjects (332) | Spouses/friends of probands collected in the DIF study, normoglycemic | Negative for GADA and IA-2A‡ | 20–91‡ | 55.5 ± 19.8‡ | N/A | 25.4 ± 4.0‡ | 45 | N/A |
Data are means ± SD unless otherwise indicated.
Antibody measurements were made in the accredited laboratory of Professor Bingley (University of Bristol) for the UKPDS, Exeter YT2D, and Diabetes in Families (DIF) cohorts and in the laboratory of Professor Bottazzo (Royal London Hospital) for the W2 Repository.
At diagnosis;
at time of sample collection.